Publication in Frontiers in Pain Research

Announced: July 23, 2026

Five months after announcing their collaboration, Lilac Biosciences and Soin Neuroscience reported the publication of a joint peer-reviewed clinical review in Frontiers in Pain Research. The publication presents a translational roadmap for bringing RNA biomarker research into routine clinical management of neuropathic pain.

Publication Title

“New Insight into RNA Biomarkers in Neuropathic Pain: A Clinician and Neuroscientist Roadmap to Translational Testing and Treatment Monitoring.”

Major Themes

The review discusses:

• Current challenges in objectively diagnosing neuropathic pain.
• Emerging evidence supporting RNA biomarkers as measurable indicators of disease activity.
• Potential clinical workflows integrating RNA testing into pain management.
• Opportunities for monitoring treatment response using molecular data.
• Future research directions needed before widespread clinical adoption.

Clinical Significance

Neuropathic pain remains difficult to quantify because physicians often rely primarily on patient descriptions. The authors argue that RNA-based biomarkers could:

• Improve diagnostic accuracy.
• Help identify patients most likely to respond to treatment.
• Track disease progression objectively.
• Monitor effectiveness of neuromodulation and other therapies over time.

This publication moves the collaboration beyond an announced partnership and into peer-reviewed scientific literature, strengthening the credibility of Lilac’s RNA biomarker platform.

Why It Matters

Publication in a peer-reviewed journal demonstrates scientific validation and positions Lilac as an emerging contributor to precision medicine approaches in chronic pain.